LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (Nasdaq: CBRX) has entered into an asset purchase agreement with Actient Pharmaceuticals LLC (“Actient”), a privately-held specialty therapeutics company, for STRIANT® (testosterone buccal system) in the United States.
